A modified live canine parvovirus strain with novel plaque characteristics. I. Viral attenuation and dog response.
A canine parvovirus (CPV) strain (C-780916) was found attenuated for pups at 80, but not after 51 serial passages in dog kidney cell (DKC) cultures. A variant viral population ('large plaque') emerged after prolonged cultivation in DKC cultures that may be associated with reduced native virulence. Dogs vaccinated with modified CPV developed high hemagglutination-inhibiting (HI) antibody titers within 4 days of incoluation and antibody persisted. Vaccinated animals shed small amounts of virus in the feces that spread to contact dogs. After five back-passages in dogs the modified strain was not pathogenic for pups and the plaque characteristics of the virus isolated from the feces were typical of the attenuated strain. The modified live CPV did not cause infection of the fetus when inoculated parenterally into pregnant bitches at various stages of gestation. It was not pathogenic for neonatal pups. These results suggest that a safe and effective live homologous (CPV) vaccine has been developed which should aid substantially in controlling CPV infection.
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D002478:Cells, Cultured; D004285:Dogs / Q000276:immunology / Q000382:microbiology*; D005243:Feces / Q000382:microbiology; D005260:Female; D010321:Parvoviridae / Q000254:growth & development* / Q000276:immunology / Q000302:isolation & purification; D011247:Pregnancy; D010948:Viral Plaque Assay; D014774:Virulence
D000914:Antibodies, Viral